Answers are grounded in this paper and cite their sources.
In patients with ARVC and ICDs, younger age is a strong predictor of device-related anxiety and poor acceptance, highlighting the need for structured psychosocial interventions and counseling.
HomeCirculation: Cardiovascular GeneticsVol. 5, No. 1Anxiety in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy and Implantable Cardioverter Defibrillators Free AccessEditorialPDF/EPUBAboutView PDFSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBAnxiety in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy and Implantable Cardioverter Defibrillators Sharlene M. Day, MD Sharlene M. DaySharlene M. Day From the Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI. Originally published1 Feb 2012https://doi.org/10.1161/CIRCGENETICS.111.962639Circulation: Cardiovascular Genetics. 2012;5:2–4Diagnosis of a cardiac genetic disorder can be a life-changing event. Symptomatic status, uncertainty regarding disease progression, risk of sudden cardiac death (SCD), recommended lifestyle changes (ie, activity restrictions or career change), and genetic transmission to offspring all contribute to the potential psychological burden of disease. Most of the relevant literature on this topic focuses on 2 of the most common genetic cardiac diseases, hypertrophic cardiomyopathy and inherited long-QT syndrome. Studies on these disorders have consistently shown impairments in health status and quality of life, with an elevated risk for anxiety and depression.1–4 An implantable cardioverter defibrillator (ICD) may be indicated for primary or secondary prevention of SCD in these patients, and is likely to exacerbate psychological distress. Independent of underlying diagnosis, patients requiring ICDs commonly experience anxiety and/or depression related to the anticipation of a potential shock.5,6 Psychological implications of ICDs have been reported to be worse in patients with inherited diseases compared with ischemic or valvular heart disease.7 The experience of receiving 1 or more ICD shocks further negatively affects quality of life.7,8 Inappropriate shocks (ie, for sinus or supraventricular tachycardia or T-wave oversensing) can elicit similar psychological responses to appropriate shocks for life-threatening ventricular arrhythmias. This is a particularly important consideration for young patients because 1 in 4 may be expected to receive at least 1 inappropriate shock.9Article see p 18Like hypertrophic cardiomyopathy and long-QT syndrome, a diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC) carries the psychological burden of genetic transmission and risk of SCD, but patients and their health care providers face unique challenges that often begin with making the diagnosis itself. Although the modified task force criteria have improved the sensitivity without loss of specificity for diagnosis,10 the broad spectrum of disease, and prolonged concealed phase during which ventricular arrhythmias can occur in the absence of other definitive clinical findings, can cause a great deal of uncertainty. Further complicating the picture is the lack of systematic criteria for prophylactic ICD implantation in ARVC patients or asymptomatic gene mutation carriers. Recent data suggest high rates of appropriate ICD discharges in ARVC patients without prior ventricular tachycardia or fibrillation, with syncope being the only multivariate predictor of a life-saving ICD shock.11 Yet, too often, a patient's first syncopal event results in death, making the absence of syncope an inadequate determinant of the need for ICD implantation. Unfortunately, despite the obvious value of an ICD in conferring protection against SCD in ARVC, the high rates of inappropriate shocks (19%) and device-related complications (17%) continue to be problematic.10 These complex issues surrounding the diagnosis and treatment algorithms for ARVC mean that extrapolation of data from the hypertrophic cardiomyopathy and long-QT syndrome literature relevant to the psychological impact of disease may underestimate its true prevalence and magnitude in this population. Only 1 recent study included ARVC patients in its assessment of health status and quality of life in those with cardiac genetic disease, and the number was small (n=17), representing only 4% of the entire cohort.4In this issue of Circulation: Cardiovascular Genetics, James et al12 examine psychosocial adjustment, anxiety, and depression in 86 adult ARVC patients with ICDs. They use 4 questionnaires that assess ICD-specific anxiety (Functional Self-Appraisal Scale), device acceptance (Florida Patient Acceptance Survey), generalized anxiety and depression (Hospital Anxiety and Depression Scale), and functional capacity (Duke Activity Status Index [DASI]). They analyze associations with demographic characteristics, including sex, age, family history of ARVC, time since ICD implantation, and history of ICD shocks. The population was high risk, with more than half having received ICDs for secondary prevention, and a similar fraction having experienced at least 1 shock (most were appropriate shocks). Despite this, the mean functional capacity was high, with a DASI score of 48.1 (ceiling value, 58.2), corresponding to an estimated peak oxygen uptake of 30.3 mL/kg per minute, which was more favorable than those of other ICD populations (mean DASI score, 17–21).13 This finding reflects the relative disconnect between arrhythmia risk and extent of structural and functional remodeling in ARVC.Device acceptance scores in ARVC patients were in the range consistent with other ICD patients in previously published studies. Younger age was a significant multivariate predictor of poor device acceptance, driven by significantly lower scores on the body image and device-related distress subscales. Similarly, younger age was an independent predictor of higher ICD-specific anxiety, for which overall scores were worse than for other published ICD populations. Other multivariate predictors of higher device-related anxiety in ARVC patients included previous ICD shocks, shorter duration from device implantation, and lower functional capacity. The same factors predicted clinically significant anxiety and depression, which were evident in 31% and 9% of respondents, respectively. Surprisingly, female sex was not associated with higher levels of anxiety or depression.This is a timely and meaningful study that addresses a frequently neglected aspect of clinical care for ARVC patients. Although recommendations for ICD implantation in ARVC patients obviously need to be driven by clinical data and perceived SCD risk, a balanced discussion that incorporates an assessment of likelihood of poor psychological adjustment to a device is extremely important. Recognition of risk predictors for poor adjustment and anxiety found in this study will greatly facilitate identification of patients who might benefit from more extensive counseling.This study raises several questions that deserve further attention in future studies. Perhaps most important will be trying to dissect out to what extent the presence of anxiety or depression is attributable to the diagnosis of ARVC itself, as opposed to the necessity or consequences of a device. This will be challenging, particularly in the Unites States, where rates of device placement in ARVC patients (particularly probands) are high, and indications obviously correlate with higher risk of SCD. Given the strong association between younger age and anxiety scores in this study, assessment of psychological distress in children with ARVC and their parents will be critical. It will also be important to assess the psychological impact of device complications and inappropriate shocks in this population. The influence of other variables on anxiety, such as genetic status and participation and/or restriction from athletic participation, would also be worth exploring.The data presented herein provide a cogent argument that we should be considering structured psychosocial interventions for patients deemed to be at particularly high risk for disease- or device-related anxiety or for those experiencing postshock traumatic stress. The most successful strategies for reducing anxiety in ICD patients involve cognitive-behavioral therapy to teach techniques to improve coping skills and illness appraisal, such as developing a shock plan and strategies to reduce negative thoughts.13–15 Other important components of psychological intervention include ICD-specific education, symptom and stress management training, and group therapy. Finally, exercise training as part of a comprehensive cardiac rehabilitation program has reduced anxiety and depression and improved quality of life in ICD patients.16,17 However, these studies enrolled older adults (mean age, late 50s), and the largest one specifically excluded patients with genetic arrhythmias,13 so it remains to be seen whether similar interventions will be equally feasible and successful at reducing anxiety and improving quality of life in ICD patients with ARVC and other inherited cardiac diseases. Any intervention using an exercise component in ARVC patients will need to be carefully tailored, with direct input from the cardiologist, to ensure safe exercise practices.James et al12 should be commended on bringing to attention the risk for poor psychosocial adjustment in patients with ARVC and ICDs. This response is one that cardiologists often overlook and urgently needs further attention and direction.Sources of FundingDr Day is supported by the National Institutes of Health.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to Sharlene M. Day, MD, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Medical Center, 1150 W Medical Center Dr, 7301 MSRB III, Ann Arbor, MI 48109. E-mail [email protected]edu.REFERENCES1. Cox S, O'Donoghue AC, McKenna WJ, Steptoe A. Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy. Heart. 1997; 78:182–187.CrossrefMedlineGoogle Scholar2. Hamang A, Eide GE, Nordin K, Rokne B, Bjorvatn C, Oyen N. Health status in patients at risk of inherited arrhythmias and sudden unexpected death compared to the general population. BMC Med Genet. 2010; 11:27.CrossrefMedlineGoogle Scholar3. Morgan JF, O'Donoghue AC, McKenna WJ, Schmidt MM. Psychiatric disorders in hypertrophic cardiomyopathy. Gen Hosp Psychiatry. 2008; 30:49–54.CrossrefMedlineGoogle Scholar4. Ingles J, Yeates L, Hunt L, McGaughran J, Scuffham PA, Atherton J, Semsarian C. Health status of cardiac genetic disease patients and their at-risk relatives [published online ahead of print September 17, 2011]. Int J Cardiol. http://dx.doi.org/10.1016/j.ijcard.2011.08.083.Google Scholar5. Matchett M, Sears SF, Hazelton G, Kirian K, Wilson E, Nekkanti R. The implantable cardioverter defibrillator: its history, current psychological impact and future. Expert Rev Med Devices. 2009; 6:43–50.CrossrefMedlineGoogle Scholar6. Wallace RL, Sears SF, Lewis TS, Griffis JT, Curtis A, Conti JB. Predictors of quality of life in long-term recipients of implantable cardioverter defibrillators. J Cardiopulm Rehabil. 2002; 22:278–281.CrossrefMedlineGoogle Scholar7. Jacq F, Foulldrin G, Savoure A, Anselme F, Baguelin-Pinaud A, Cribier A, Thibaut F. A comparison of anxiety, depression and quality of life between device shock and nonshock groups in implantable cardioverter defibrillator recipients. Gen Hosp Psychiatry. 2009; 31:266–273.CrossrefMedlineGoogle Scholar8. Passman R, Subacius H, Ruo B, Schaechter A, Howard A, Sears SF, Kadish A. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study. Arch Intern Med. 2007; 167:2226–2232.CrossrefMedlineGoogle Scholar9. Lewandowski M, Sterlinski M, Maciag A, Syska P, Kowalik I, Szwed H, Chojnowska L, Przybylski A. Long-term follow-up of children and young adults treated with implantable cardioverter-defibrillator: the authors' own experience with optimal implantable cardioverter-defibrillator programming. Europace. 2010; 12:1245–1250.CrossrefMedlineGoogle Scholar10. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MGPJ, Daubert JP, Fontaine G, Gear K, Hauer R, Nava A, Picard MH, Protonotarios N, Saffitz JE, Sanborn DMY, Steinberg JS, Tandri H, Thiene G, Towbin JA, Tsatsopoulou A, Wichter T, Zareba W. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation. 2010; 121:1533–1541.LinkGoogle Scholar11. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, Basso C, Ward D, Boriani G, Ricci R, Piccini JP, Dalal D, Santini M, Buja G, Iliceto S, Estes III NAM, Wichter T, McKenna WJ, Thiene G, Marcus FI. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation. 2010; 122:1144–1152.LinkGoogle Scholar12. James CA, Tichnell C, Murray B, Daly A, Sears SF, Calkins H. General and disease-specific psychosocial adjustment in arrhythmogenic right ventricular dysplasia/cardiomyopathy patients with implantable cardioverter defibrillators: a large cohort study. Circ Cardiovasc Genet.2012; 5:18–24.LinkGoogle Scholar13. Dunbar SB, Langberg JJ, Reilly CM, Viswanathan B, McCarty F, Culler SD, O'Brien MC, Weintraub WS. Effect of a psychoeducational intervention on depression, anxiety, and health resource use in implantable cardioverter defibrillator patients. Pacing Clin Electrophysiol. 2009; 32:1259–1271.CrossrefMedlineGoogle Scholar14. Pedersen SS, van den Broek KC, Sears SF. Psychological intervention following implantation of an implantable defibrillator: a review and future recommendations. Pacing Clin Electrophysiol.2007; 30:1546–1554.CrossrefMedlineGoogle Scholar15. Sears SF, Sowell LD, Kuhl EA, Kovacs AH, Serber ER, Handberg E, Kneipp SM, Zineh I, Conti JB. The ICD shock and stress management program: a randomized trial of psychosocial treatment to optimize quality of life in ICD patients. Pacing Clin Electrophysiol. 2007; 30:858–864.CrossrefMedlineGoogle Scholar16. Frizelle DJ, Lewin RJ, Kaye G, Hargreaves C, Hasney K, Beaumont N, Moniz-Cook E. Cognitive-behavioural rehabilitation programme for patients with an implanted cardioverter defibrillator: a pilot study. Br J Health Psychol. 2004; 9:381–392.CrossrefMedlineGoogle Scholar17. Fitchet A, Doherty PJ, Bundy C, Bell W, Fitzpatrick AP, Garratt CJ. Comprehensive cardiac rehabilitation programme for implantable cardioverter-defibrillator patients: a randomised controlled trial. Heart. 2003; 89:155–160.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Manuel A and Brunger F (2016) Embodying a New Meaning of Being At Risk, Global Qualitative Nursing Research, 10.1177/2333393616674810, 3, (233339361667481), Online publication date: 1-Jan-2016. Etchegary H, Pullman D, Simmonds C, Young T and Hodgkinson K (2014) 'It had to be done': genetic testing decisions for arrhythmogenic right ventricular cardiomyopathy, Clinical Genetics, 10.1111/cge.12513, 88:4, (344-351), Online publication date: 1-Oct-2015. Agrimi J, Scalco A, Agafonova J, Williams III L, Pansari N, Keceli G, Jun S, Wang N, Mastorci F, Tichnell C, Murray B, James C, Calkins H, Zaglia T, Paolocci N and Chelko S (2020) Psychosocial Stress Hastens Disease Progression and Sudden Death in Mice with Arrhythmogenic Cardiomyopathy, Journal of Clinical Medicine, 10.3390/jcm9123804, 9:12, (3804) February 2012Vol 5, Issue 1 Advertisement Article InformationMetrics © 2012 American Heart Association, Inc.https://doi.org/10.1161/CIRCGENETICS.111.962639 Originally publishedFebruary 1, 2012 Keywordsarrhythmogenic right ventricular cardiomyopathyimplantable cardioverter defibrillatorgenetic heart diseasepsychosocialEditorialsPDF download Advertisement SubjectsBehavioral/Psychosocial TreatmentCardiomyopathyCatheter Ablation and Implantable Cardioverter-DefibrillatorGenetics
No takes yet. Share an insight, caveat, or question.
Sharlene M. Day (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: